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the changes to the PTSD criteria in DSM‑5, 
and the  repercussions this has for screen‑
ing, assessment, and treatment practices for 
cancer‑related stress problems.
DSM-5: TrauMa anD STreSS-relaTeD 
DiSorDerS
In DSM‑5, disorders which are precipitated 
by specific stressful and potentially trau‑
matic events are included in a new diag‑
nostic category, “Trauma and Stress‑Related 
Disorders,” which includes both Adjustment 
Disorders (ADs) and PTSD (5). Friedman 
and his colleagues (6) assert that there is 
heuristic value in grouping this set of dis‑
orders in a specific stress‑related category as 
it enables clinicians to differentiate between 
normal (non‑pathological) distress, from 
acute, diffuse clinically elevated stress 
reactions indicative of AD, to more severe 
and chronic psychopathology (including 
PTSD). This heuristic framework also has 
potential utility for delineating psychologi‑
cal disturbances arising from cancer‑related 
stress. It brings to the forefront the impor‑
tance of carefully differentiating whether a 
patient’s stress reactions pertaining to their 
cancer experience are acute, yet interfering 
with functioning, indicative of AD, or more 
severe psychopathology such as PTSD.
Although ADs have been documented to 
be highly prevalent in cancer patients rang‑
ing up to 35% (7, 8), they have tended to 
be overlooked in studies specifically investi‑
gating the prevalence and characteristics of 
ca‑PTSD. Since the publication of DSM‑IV, 
from the studies which have examined the 
incidence or prevalence of ca‑PTSD utiliz‑
ing clinical diagnostic interviews, only a 
handful have differentially evaluated the 
occurrence of partial/sub‑threshold PTSD 
symptoms relative to AD or other anxiety 
or mood disorders [e.g., Ref. (9–11)]. From 
this small cohort of studies, the prevalence 
inTroDucTion
It is well documented that being diagnosed 
and treated for cancer is understandably, 
a challenging experience associated with 
heightened distress. To this end, in 2009, 
the International Psycho‑Oncology Society 
endorsed distress as the sixth vital sign in 
cancer care (1). Indeed, cancer‑related dis‑
tress is common at pivotal periods in the 
prototypical trajectory of a cancer patients’ 
experience (including the diagnostic, treat‑
ment, recovery, and recurrence phases); 
and ranges on a continuum from normal, 
acute responses which may comprise ini‑
tial fear post‑diagnosis, to more severe, 
potentially chronic stress reactions that 
adversely impact functionality and general 
well‑being. Therefore, in the Fourth Edition 
of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM‑IV), being diag‑
nosed with a life‑threatening illness such 
as cancer was included for the first time as a 
potential traumatic event that could induce 
posttraumatic stress disorder (PTSD) (2).
Since 1994, there has been a proliferation 
of studies investigating the prevalence and 
characteristics of cancer‑related PTSD (ca‑
PTSD) [see reviews, (3, 4)]. The majority 
of research has been based on self‑report 
questionnaires which has tended to inflate 
the rates of ca‑PTSD (with prevalence rates 
as high as 55%) compared to studies that 
have used the gold‑standard assessment 
method of structured, clinical diagnostic 
interviews (4). In fact, the prevalence rate 
for ca‑PTSD has been documented to be 
considerably lower when utilizing the lat‑
ter approach, ranging from 0 to 22% (3). 
With the Fifth Edition of DSM [DSM‑5; 
(5)], there are some notable changes to 
screening for stress‑related disorders and 
which have important implications for 
screening cancer patients and survivors. 
The purpose of this paper is to evaluate 
of ca‑PTSD compared to AD has been quite 
variable. Whereas some studies have found 
a much higher prevalence of AD relative 
to ca‑PTSD [e.g., 20 vs. 2% (11); 7 vs. 2% 
(12)], other studies have found ca‑PTSD 
is more prevalent than AD [e.g., 5 vs. 2% 
(13)]. These mixed outcomes may in part 
be due to differences in the timing of the 
assessment (i.e., time elapsed since cancer 
diagnosis and treatment completion), as 
well as in diagnostic approaches utilized to 
screen for ca‑PTSD relative to AD and other 
types of anxiety and mood disorders.
A close inspection of the ca‑PTSD lit‑
erature indicates that a greater proportion 
of patients meet sub‑threshold symptoms 
for PTSD rather than full diagnostic cri‑
teria [e.g., 33 vs. 5% full‑PTSD (14); 13.6 
vs. 0% full‑PTSD (15); 20.3 vs. 16.2% full‑
PTSD (16)]. In accordance with DSM‑IV 
(2) and DSM‑5 criteria (5), an AD diagno‑
sis should be considered for persons who 
only meet partial criteria for PTSD, and if 
these symptoms are not better accounted by 
another type of anxiety or depressive disor‑
der. However, the majority of cancer studies 
which have assessed PTSD symptoms, have 
not considered whether AD, or even another 
anxiety or mood disorder may better repre‑
sent the symptom profile for at least some 
cancer patients who elicit persistent distress 
for more than one month. To this end, the 
changes to some core criteria for PTSD in 
DSM‑5 will necessitate a more differential 
approach to assessing the symptom profile 
of stress reactions in cancer patients.
DSM-5 PTSD criTeria: Key changeS 
anD iMPlicaTionS for cancer 
PaTienTS anD SurvivorS
Criterion A has been tightened with DSM‑
5. Importantly, a clear caveat has been 
included which notes that “A life threaten-
ing illness or debilitating  medical condition is 
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defines a person’s intrusive reactions then 
these  symptoms do not qualify for ca‑PTSD. 
Similarly, Criteria B2, B4, and B5 (distress‑
ing dreams, emotional, and physiologi‑
cal) symptoms need to also be assessed in 
context of AD and other anxiety disorders, 
particularly if the individuals fears are pri‑
marily future‑oriented.
In DSM‑5, separating the PTSD avoid‑
ance from the numbing and cognitive symp‑
toms into two distinct clusters (Criteria C 
and D respectively) has the potential to 
further reduce the rates of false‑positive 
ca‑PTSD. Previously, according to PTSD‑
DSM‑IV Criterion C, a person with can‑
cer could have met this criterion without 
reporting avoidance reactions. However, 
individuals must now elicit at least one 
avoidance symptom to meet Criterion C 
and which is directly related to avoidance of 
“distressing cancer memories” (i.e., cancer‑
events that have transpired).
The proposed new Criterion D (numb‑
ing/dissociative and negative cognitive 
reactions) also has the scope to enhance 
diagnostic sensitivity and specificity. Three 
of the seven symptoms (Criterion D2, 
D3, and D7) are new or amended criteria. 
Criterion D2 has been modified from “a 
sense of foreshortened future” (Criterion 
C7, PTSD‑DSM‑IV) and expanded to cap‑
ture negative distorted attributions about 
the self, others, or the world post‑trauma. 
Criterion D3 assesses whether a person 
elicits unrealistic blame of self or others 
pertaining to the cause or consequences of 
their stressor experience. However, attribu‑
tions of self‑blame may be grounded in real‑
ity for some cancer patients. For example, 
a person who has been a chronic smoker 
and subsequently develops lung cancer may 
understandably elicit self remorse for their 
lifestyle choice. However, if these symptoms 
are accompanied by exaggerated self‑dep‑
recating schemas, this may also be indica‑
tive of depression. Criterion D4 expands 
upon the previous subjective Criterion A2 
(in DSM‑IV) in order to capture a wider 
range of pervasive emotional reactions 
post‑trauma which includes feelings of 
guilt, shame, and anger. The four remain‑
ing Criterion D numbing and dissociative 
symptoms (D1, D5, D6, and D7) remain the 
same from DSM‑IV, PTSD criteria.
The fourth cluster, Criterion E now 
includes reactive as well as arousal symp‑
toms. Specifically, Criterion E1 has been 
not necessarily considered a traumatic event. 
Medical incidents that qualify as traumatic 
events involve sudden, catastrophic events” 
[(5), p. 274]. Hence, a diagnosis or being 
treated for cancer per se with no adverse 
events is not necessarily sufficient to qual‑
ify for a PTSD diagnosis. Furthermore, 
for family and friends, “witnessed events” 
include “unnatural death”; and “learning” 
about threatening life events must be vio‑
lent or accidental. Therefore, learning about 
a relative’s cancer, or death resulting from 
cancer would not qualify as a PTSD stressor. 
Similarly, this exclusion criterion is also 
applicable for persons who learn that they 
have a genetic vulnerability to developing 
cancer in terms of carrying a particular can‑
cer gene. In such circumstances, although 
this information is stressful, if a person elic‑
its heightened, persistent stress reactions, 
an alternative diagnosis needs to be con‑
sidered contingent on profile and duration 
of symptoms, including AD, Generalized 
Anxiety Disorder, as well considering the 
relevancy of Illness Anxiety Disorder, or 
Somatic Symptom Disorder.
If an individual does experience adverse 
cancer‑related events, they would also need 
to meet the four core criteria that now com‑
prise PTSD (Criteria B to E), instead of the 
three core clusters stipulated in DSM‑IV 
PTSD criteria. This change is in line with 
at least 10 published factor analytic studies 
[see Ref. (17)], including two cancer stud‑
ies (16, 18), which have found that a four‑
factor model provides a better fit for the 
PTSD construct. This has the propensity to 
tighten the sensitivity threshold in identify‑
ing persons whose stress reactions reflect 
PTSD relative to other anxiety and mood 
disorders. In particular, the four core PTSD 
clusters require that an individual elicits at 
least one of five re‑experiencing symptoms 
(Criterion B), one of two avoidance symp‑
toms (Criterion C), two of seven dissocia‑
tive and/or negative cognitive symptoms 
(Criterion D), and two of six arousal and 
reactivity symptoms (Criterion E).
Although minimal changes have been 
proposed for the re‑experiencing (Criterion 
B) cluster, the reporting of intrusive symp‑
toms need to be evaluated in relation 
to “involuntary and intrusive distressing 
memories” (Criterion B1). This is in con‑
trast to individuals worrying about their 
future health including fear of cancer 
recurrence. If these latter responses better 
expanded to include unprovoked anger 
outbursts, and the new Criterion E2 cap‑
tures reckless or self‑destructive behav‑
ior. Although these symptoms have been 
reported in veteran and non‑medical 
trauma samples, there is a paucity of studies 
that have indicated whether such symptoms 
also arise in distressed cancer patients.
Furthermore, although the criteria for 
duration (Criterion F) and functionality 
(Criterion G) have remained the same in 
DSM‑5 (i.e., the constellation of symptoms 
endure for more than 1‑month, and result 
in impairment in one or more areas of inter‑
personal and/or occupational functioning), 
the expansion of the core criteria to four 
core clusters, with particular emphasize of 
involuntary and distressing intrusive mem‑
ories is likely to reduce the prevalence of ca‑
PTSD. This is because there is an increasing 
body of literature that demonstrates that 
most distressed cancer patients tend to be 
worried about current and future health 
concerns, including fears of cancer recur‑
rence [e.g., Ref. (19)], instead of eliciting and 
avoiding intrusive, involuntary, distressing 
cancer‑related memories. Moreover, with 
the inclusion of AD in the new category of 
Trauma and Stress‑Related Disorders, it is 
timely for the psycho‑oncology field to re‑
consider the utility of AD as well as other 
anxiety and mood disorders in screening for 
clinical stress reactions in cancer patients. 
Indeed, the DSM‑5 stipulates that ADs “are 
common accompaniments of medical illness 
and may be the major psychological response 
to a medical disorder” [(5), p. 289].
concluSion
With the introduction of the “Trauma 
and Stress‑Related Disorders” category in 
DSM‑5, the pertinent issue is not whether 
AD better defines clinically elevated cancer‑
related stress reactions compared to PTSD, 
or whether either or both of these frame‑
works have utility for defining heightened 
ca‑related distress beyond other mental 
health disorders. Rather, these changes 
have important clinical implications in 
 identifying cancer patients and longer‑
term survivors who are experiencing psy‑
chopathology. It is recommended that 
clinicians (and researchers) carefully con‑
sider differential diagnostic parameters as 
well as screening for psychological history 
(pre‑cancer diagnosis) when evaluating 
stress reactions in cancer patients. Indeed, 
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most psycho‑oncology studies to date have 
 overlooked screening for patients’ psychi‑
atric history, resulting in probable overes‑
timation of prevalence rates. To this end, 
screening patients’ psychiatric history is 
important to ascertain whether distress 
reactions elicited post‑cancer diagnosis 
are an exacerbation or recurrence of pre‑
existing mental health problems (includ‑
ing other anxiety and depressive disorders) 
compounded by the stress of adjusting to 
one’s cancer diagnosis. Moreover, this has 
important treatment implications in ensur‑
ing an appropriate evidence based therapy 
is recommended to patients. For example, 
presently, the strongest supported evidence 
for the treatment of PTSD is Trauma‑
Focused Cognitive Behavioral Therapy 
(TF‑CBT) which includes imaginal expo‑
sure targeting sub‑traumatic memory per‑
taining to the trauma experience (20). If 
however, a cancer patient’s diffuse stress 
symptoms are misdiagnosed as ca‑PTSD, 
applying an imaginal exposure compo‑
nent as part of a TF‑CBT program may 
be ineffective and lead to poor or delayed 
treatment gains. Hence, accuracy in diag‑
nosing ca‑PTSD relative to AD and other 
types of anxiety and mood disorders has 
direct implications for selecting appro‑
priate treatments for client benefits. It is 
therefore timely with the shift to DSM‑5, 
that a more comprehensive approach in 
screening for debilitating stress problems in 
cancer patients is utilized, which takes into 
account patients’  psychological history.
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